A phase I study of the myeloid cell leukemia 1 (MCL1) inhibitor tapotoclax (AMG 176) in patients with myelodysplastic syndromes after hypomethylating agent failure

Kelly S. Chien, Juan Jose Rodriguez-Sevilla, Yesid Alvarado, Guillermo Montalban-Bravo, Danielle E. Hammond, Mahesh Swaminathan, Alexandre Bazinet, Jacqueline Kimberley, Kristy Bodden, Heather Schneider, Xiao Qin Dong, Sherry A. Pierce, Xuelin Huang, Elias J. Jabbour, Hagop M. Kantarjian, Guillermo Garcia-Manero

Research output: Contribution to journalLetterpeer-review

Original languageEnglish (US)
Article number107602
JournalLeukemia Research
Volume147
DOIs
StatePublished - Dec 2024

Keywords

  • Hypomethylating agent failure
  • MCL1
  • MCL1 inhibitor
  • MDS
  • Myelodysplastic syndrome
  • Tapotoclax

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this